However, as the SIX1-Q177R ChIP-seq data had been obtained from a single chemotherapy-treated Wilms tumor (Wegert et al., 2015), we first sought to investigate the DNA-binding preference of the mutant protein in the absence of potentially confounding variables, including tissue quality, chemotherapy-induced artefacts and interacting protein co-factors that can shift the DNA-binding preference of transcription factors (Siggers et al., 2011; Slattery et al., 2011). This evidence concerns the gene SIX1 and Nephroblastoma.